Azithromycin intravenous (IV) is indicated for the treatment of community acquired pneumonia (CAP) caused by susceptible organisms, including Legionella pneumophila, in patients who require initial intravenous therapy.
Azithromycin intravenous (IV) is indicated for the treatment of pelvic inflammatory disease (PID) caused by susceptible organisms (Chlamydia trachomatis, Neisseria gonorrhoea, Mycoplasma hominis), in patients who require initial intravenous therapy.